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Introduction: Online haemodiaﬁltration (OL-HDF) is most effective technique; several ran-
domised studies and meta-analyses have shown a reduction in mortality, with a directly
related association with convective volume. At present, it is not properly established
whether the increasing in dialyser surface area may suppose better outcomes in terms
of convective and clearance efﬁcacy. The purpose of the study was to assess the effect of
increase in dialyser surface area on the convective volume and clearance capacity.
Materials and methods: A total of 37 patients were included, 31 male and 6 female subjects
who were participating in an OL-HDF programme with a 5008 Cordiax monitor with auto-
substitution. Each patient was analysed in three sessions, and only the dialyser surface area
(1.0, 1.4 or 1.8m2) varied. In each session, urea (60Da), creatinine (113Da), 2-microglobulin
(11,800Da), myoglobin (17,200Da) and 1-microglobulin (33,000Da) serum concentration at
baseline and at the end of each session were determined, so the reduction of thes solutes
could be calculated.
Results: Convective volume achieved was 29.8±3.0 with 1.0m2, 32.7±3.1 (6% increase) with
1.4m2 and 34.7±3.3 L (16% increase) with 1.8m2 (p<0.001). The increase in dialyser surface
area showed an increase in urea andCreatinine clearance andurea and creatinine clearance.
The reduction percentage of 2-m increased from 80.0±5.6 with 1.0m2, to 83.2±4.2 with
2 21.4m and to 84.3±4.0% with 1.8m . Regarding myoglobin and 1-microglobulin, signiﬁcantdifferenceswere observed between the smallest surface area (1.0m2), 65.6±11 and 20.1±9.3
and the other two surface areas, 70.0±8.1 and 24.1±7.1 (1.4m2) and 72.3±8.7 and 28.6±12
(1.8m2).
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Conclusion: The increase in 40% and 80% of dialyzer surface area entails an increase in con-
vective volume of 6 and 16% respectively, showing minimal differences both in convective
volume and clearance capacity when UFC was greater than 45mL/h/mmHg. It is advisable
to optimise dialyser efﬁciency to the smallest surface area possible, adjusting treatment
prescription.
© 2015 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española de
Nefrología. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Valoración de la superﬁcie del dializador en la hemodiaﬁltración on-line.
Elección objetiva de la superﬁcie del dializador
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Introducción: La hemodiaﬁltración on-line (HDF-OL) es actualmente la técnica más efectiva.
Varios estudios aleatorizados y metaanálisis han observado una reducción de la mortalidad,
objetivándose una asociación en relación directa con el volumen convectivo. En el momento
presente no está bien establecido si el aumento de superﬁcie del dializador puede suponer
mejores resultados en términos de eﬁcacia convectiva y depurativa. El objetivo del estudio
fue valorar el efecto del aumento de superﬁcie del dializador sobre el volumen convectivo
y la capacidad depurativa.
Material y métodos: Se incluyeron 37 pacientes (31 varones y 6 mujeres) que se encontraban
en programa de HDF-OL con monitor 5008Cordiax con autosustitución. Cada paciente fue
analizado en 3 sesiones en las que solo se varió la superﬁcie del dializador (1,0, 1,4 o 1,8m2).
En cada sesión se determinaron la concentración de urea (60Da), creatinina (113Da), 2-
microglobulina (11.800Da), mioglobina (17.200Da) y 1-microglobulina (33.000Da) en suero
al inicio y al ﬁnal de cada sesión, para calcular el porcentaje de reducción de estos solutos.
Resultados: El volumen convectivo alcanzado fue de 29,8±3,0 con 1,0m2, de 32,7±3,1 (incre-
mento del 6%) con 1,4m2 y de 34,7±3,3 l (incremento del 16%) con 1,8m2 (p<0,001). El
incremento de la superﬁcie del dializador mostró un aumento de la dosis de diálisis y de la
depuración de urea y creatinina. El porcentaje de reducción de 2-microglobulina se incre-
mentó de 80,0±5,6 con 1,0m2, a 83,2±4,2 con 1,4m2 y a 84,3±4,0% con 1,8m2. Respecto a la
mioglobina y la a1-microglobulina, se observaron diferencias signiﬁcativas entre la menor
superﬁcie (1,0m2) 65,6±11 y 20,1±9,3; y las otras 2 superﬁcies 70,0±8,1 y 24,1±7,1 (1,4m2)
y 72,3±8,7 y 28,6±12 (1,8m2).
Conclusión: El incremento del 40 y el 80% de la superﬁcie conlleva un aumento del volu-
men convectivo de un 6 y un 16%, respectivamente, mostrando mínimas diferencias tanto
en el volumen convectivo como en la capacidad depurativa cuando el CUF era superior a
45ml/h/mmHg. Es recomendable optimizar el rendimiento de los dializadores a la mínima
superﬁcie posible adecuando la prescripción de tratamiento.
© 2015 The Authors. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española
de Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND
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he ESHOL1 study has shown a longer survival in those
atients receiving postdilution online HDF (OL-HDF), and
ecent meta-analyses has conﬁrmed a reduction in global
nd cardiovascular mortality.2,3 Post hoc analysis of the three
linical trials that had mortality as primary endpoint1,4,5
howed an association between convective volume and sur-
ival. In view of these results, obtaining a total convective
olume greater than 21L per session has been recommended
iven the lack of more concluding scientiﬁc evidence.6 The
ain limiting factors to obtaining high convective volumes
re the blood ﬂow (Qb), the time and the dialyser.(http://creativecommons.org/licenses/by-nc-nd/4.0/).
In a previous study7 it was shown that the increase in
Qb is probably the best option to reach the highest convec-
tive volume, with an increase of more than half a litre per
hour per 50mL/min. The Qb increases the clearance capac-
ity of small molecules and favours the clearance capacity
of 2-m and myoglobin; and has no inﬂuence on higher
molecules.
The pharmaceutical industry has improved dialysers by
optimising the pore size and the inner diameter to achieve
higher substitution volumes and better clearances.8 However,
the choice of dialyser surface areahasnot beenproperly estab-
lished. In Spain, some groups work with surface areas ranging
from 1.8 to 2.1m2 9,10 and other groups, like ours, work with
surface areas ranging from 1.4 to 1.8m2.11,12 Other European
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countries having a long tradition of convective therapies use
high surface areas ranging from 1.8 to 2.3m2.13–15
If we consider the fact that most dialysers maintain an
ultraﬁltration coefﬁcient (UFC) higher than 40mL/h/mmHg
and high screening coefﬁcients for 2-microglobulin
(2-m) and/or myoglobin, the purpose of this study was
to assess the effect of dialyser surface area variations on
convective volume and clearance capacity thereof in patients
under treatment with OL-HDF.
Patients and methods
This is a one centre study in stable hemodialysis patents.
A total of 37 patients were included, 31 male and 6 female
with a mean age of 64.7±13 years (range 41–89), who were
participating in an HD programme for an average period of
39±35 months. Chronic kidney failure aetiology included
4 cases of chronic glomerulonephritis (10.8%), 8 cases of dia-
betic nephropathy (21.6%), 4 cases of polycystosis (10.8%),
3 cases of vascular nephropathy (8.1%), 3 cases of urologic
causes (8.1%), 2 cases of systemic diseases (5.4%), 1 case of
tubulointerstitial nephropathy (2.7%) and12 cases of unknown
aetiology (32.4%). All patients underwent dialysis through
an arteriovenous ﬁstula, except for one tunnelled central
catheter.
Each patient received three different dialysis sessions,
always in the middle of the week, where only the dialyser
surface area varied: 1.0, 1.4 or 1.8m2 (dialyser characteris-
tics are listed in Table 1). The remaining dialysis parameters
remained constant in each of the studied sessions: Helixone®
plus membrane; dialysis time, 293±16min (240–300min);
Qd 500mL/min; 5008 Cordiax monitor; postdilution OL-HDF
with autosubstitution system. The order of sessions was ran-
domised.
Dialysis parameters collected in each session were as
follows: scheduled, actual duration, dialyser, Qb, needle
gauge, dialysis bath ﬂow, Kt automatically measured by ionic
dialysance, recirculation index measured by temperature
module, blood pressure (BP), venous pressure (VP), trans-
membrane pressure (TMP), baseline and ﬁnal haemoglobin,
ultraﬁltration, processed blood volume and substitution
volume.
Table 1 – Dialyser characteristics.
Membrane FX50 Cordiax
Helixona® plus
Surface area (m2) 1.0
Wall thickness (m) 35
Inner diameter (m) 185
Urea KoA (mL/min) 886
UFC (mL/h/mmHg) 33
UFC (mL/h/mmHg/m2) 33
Sterilisation Vapour
2-Microglobulin screening coefﬁcient 0.9
Myoglobin screening coefﬁcient 0.5
Albumin screening coefﬁcient <0.001
KoA: mass transfer area coefﬁcient; UFC: ultraﬁltration coefﬁcient.;35(3):280–286
Urea (60Da), creatinine (113Da), 2-microglobulin
(11,800Da), myoglobin (17,200Da) and 1-microglobulin
(33,000Da) serum concentrations at baseline and at the end
of each session were determined to calculate the reduction
percentage of these solutes. Urea and creatinine concentra-
tions were measured by molecular absorption spectrometry
with analyser ADVIA 2400 Chemistry System of Siemens
Healthcare Diagnostics, IL, USA. 2-microglobulin and 1-
microglobulin were measured by immunonephelometry
with analyser BNII (Siemens Healthcare Diagnostics). Myo-
globin concentrations were measured by sandwich enzyme
immunoanalysis with Dimension EXL (Siemens Healthcare
Diagnostics) analyser. In all cases, dedicated reagents were
used.
To correct haemoconcentration during dialysis, pre- and
post-treatment plasma reduction percentages of 2-m, myo-
globin and 1-microglobulin were calculated using the
Bergström and Wehle formula.16
The statistical analysis was performed using the SPSS
statistical programme version 20.0 and the results were
expressed as the arithmetic mean± standard deviation. For
the analysis of statistical signiﬁcance of quantitative parame-
ters the Student’s t-test has been used for paired data, or the
ANOVA test for repeated data. A p<0.05 has been considered
statistically signiﬁcant.
Results
All dialysis sessions were performed with no signiﬁcant clini-
cal incidences. No session showeddialyser or line coagulation.
Anticoagulation therapy used was sodium heparin in 24.3% of
sessions, low-molecular-weight heparin nadroparin (32.4%) or
tinzaparin (29.7%) and in 13.5% of the remaining sessions no
heparin was used.
No differences were observed in dialysis parameters, Qb,
total blood processed by the monitor, dialysate ﬂow, actual
duration of the sessions, baseline weight, weight gain, base-
line and ﬁnal hematocrit as measured by the dialysis monitor,
needle size, vascular access recirculation, BP, VP or TMP
(Table 2).
Substitution volume was signiﬁcantly higher with the
increase in dialyser surface area (Table 3). This table also
shows the total convective volume (substitution volume plus
FX60 Cordiax FX80 Cordiax
Helixona® plus Helixona® plus
1.4 1.8
35 35
185 185
1164 1429
47 64
33.6 35.5
Vapour Vapour
0.9 0.9
0.5 0.5
<0.001 <0.001
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Table 2 – Comparison of dialysis parameters in the three study situations with dialyser surface area variation (n=37).
1.0m2 1.4m2 1.8m2 P
Qb (mL/min) 413±33 412±34 412±34 NS
Puriﬁed blood (L) 117.6±13 117.5±13 117.6±13 NS
Qd (mL/min) 500 500 500 NS
Scheduled Td (min) 291.9±17 291.9±17 291.9±17 NS
Actual Td (min) 285.5±18 286.4±19 286.0±17 NS
Baseline weight (kg) 71.49±18 71.58±18 71.73±16 NS
Final weight (kg) 69.40±16 69.41±16 69.49±16 NS
Weight gain (kg) 2.09±0.91 2.18±1.04 2.24±0.94 NS
Baseline haematocrit (%) 31.1±3.9 30.9±4.9 30.1±4.6 NS
Final haematocrit (%) 35.8±4.4 35.8±5.9 35.5±5.5 NS
Needles 15/16 (%) 90/10 90/10 90/10 NS
Recirculation (%) 12.8±3.3 12.8±3.6 13.4±3.2 NS
Blood P. (mmHg) −217±33 −213±30 −213±29 NS
Venous P. (mmHg) 211±33 211±30 209±31 NS
TMP (mmHg) 177±19 185±16 182±20 NS
MP: t
w
(
o
t
9
u
t
i
t
2
i
m
7
p
p
n
a
f
d
s
o
1
D
T
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eight gain) increased from 29.82 L with 1.0m2 to 32.7 L
increase of 9.5%) with 1.0m2 and 34.7 L with 1.8m2 (increase
f 16% in relation to 1.0m2 and 6% in relation to 1.4m2);
he average Qi in each of the situations increased from
7.2mL/min with 1.0m2 to 113.5mL/min with 1.8m2; and the
ltraﬁltrationﬂow (QUF). The calculation of the percent of efec-
ive concvective volume relative to the total processed blood,
t was observed that this value was signiﬁcantly higher with
he larger surface areas, from 25.50±2.43% with 1.0m2 to
9.65±2.7% with 1.8m2 (Fig. 1).
The increase in dialyser surface area resulted in an increase
n both the dose of dialysis and the clearance of small
olecules. The Kt increased from 68.6±6.7 L with 1.0m2 to
2.5±6.8 and 75.3±7.2 L, with 1.4m2 and 1.8m2, respectively,
< 0.001 in all situations. Fig. 2, shows the differences in the
ercent of urea and creatinine reduction, with statistically sig-
iﬁcant differences between 1.0m2 and the other two surface
reas; there were no differences between 1.4 and 1.8m2 sur-
ace areas.
Clearance of 2-m was signiﬁcatly increased in larger
ilayzers (Fig. 3). Regarding myoglobin and 1-microglobulin,
igniﬁcant differences were observed between 1.0m2 and the
ther two surface areas (Figs. 4 and 5), but not between 1.4 and
.8m2.iscussion
his study shows the comparisons of postdilutional OL-HDF
n a same dialyzer with three different surface areas, 1.0,
Table 3 – Comparison of replacement volume, total convective v
volume percentage over puriﬁed blood at different dialyser surf
Substitution volume (L/session) 27.
Convective volume (L/session) 29.
Qi (mL/min) 97
QUF (mL/min) 104
Convective volume percentage related to processed blood (%) 25.
Qi: infusion ﬂow; QUF: ultraﬁltration ﬂow.ransmembrane pressure.
1.4 or 1.8m2. It was observed that a 40% and 80% increase
in surface area entails an increase in convective volume of
6–10% and 16%, respectively. Clearance capacity expressed as
a percent reduction increased from 1% to 3% for urea (though
expressed as Kt between 4% and 9.7%) and creatinine as small
molecule markers, and from 1% to 5% for 2-m. In the case
of molecules with a greater molecular weight, myoglobin and
1-microglobulin, a higher clearancewas observed only in ses-
sions with dialysers featuring a larger surface area compared
to surface areas of 1.0m2.
OL-HDF is a safe technique which enhances intradial-
ysis haemodynamic tolerance4,17 and increases survival.4–6
The EuDial group redeﬁned HDF as the blood puriﬁcation
treatment which combines diffusive and convective trans-
port using a high-ﬂow dialyser with a UFC greater than
20mL/h/mmHg/m2, a screening coefﬁcient for 2-m greater
than 0.6 and an effective convective transport percentage
greater than 20% of the total processed blood,18 with no other
speciﬁcation related to the surface area thereof.
The main limiting factors to obtain high convective vol-
umes are Qb, the dialysis time and the haemoconcentration
in the dialyser. Due to the development of new design of the
dialyzers it has been possible to increase convective volume
with the increase in pore size or capillary ﬁbre diameter.8 This
work aims to address the role of the dialyser surface area in
obtaining the target convective volume and clearance efﬁcacy.
The convective volume reached varied from 30L with 1.0m2
to 35 L with 1.8m2, or expressed as ultraﬁltration ﬂow ran-
ging from 105 to 121mL/min, which represents an adequate
olume, infusion ﬂow, ultraﬁltration ﬂow and convective
ace areas (n=37).
1.0m2 1.4m2 1.8m2 P
74 ± 3.3 30.49 ± 3.18 32.4 ± 3.7 <0.001
82 ± 3.0 32.67 ± 3.1 34.7 ± 3.3 <0.001
.2 ± 11 106.6 ± 10 113.5 ± 12 <0.001
.6 ± 10 114.2 ± 10 121.4 ± 11 <0.001
50 ± 2.43 27.95 ± 2.44 29.65 ± 2.7 <0.001
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Fig. 1 – Convective volume variations and convective
volume percentage over puriﬁed blood based on the
dialyser surface area, n=37, ANOVA for repeated data.
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Fig. 2 – Creatinine and urea reduction percentage variations
based on the dialyser surface area, n=37, ANOVA
for repeated data.
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1.8convective dose in all study situations. Therefore, surface
area individualisation based on each patient seems reason-
able taking into account that there are dialysers with high
UFC, ranging from 33 to 64mL/h/mmHg in this work, although
many commercially marketed dialysers reach a maximum of
100mL/h/mmHg. Thismeans that a TMPof 200mmHg enables
a Qi of 110, 157 and 213mL/min with the three UFCs used,
ﬂows in the last two being higher than those which can actu-
ally be used, given the fact that to reach the Qi of 213mL/min
in the 1.8-m2 ﬁlter with the Qi/Qb coefﬁcient limitation of
33%, it would be necessary to use a Qb of at least 650mL/min,
which is within reach only for a few vascular accesses and is
rarely used in most units. In other words, we have dialysers
with a high convective capacity and the Qi limitation is mainly
due to Qb (25–33% thereof) and in a low percentage the limita-
tion is in the dialyser UFC. Therefore, the issue raised relates
to whether the dialyser is duly used to the fullest or not. In this
work, with an average TMP of 200mmHg, this means that out
of the aforementioned theoretical convective capacity, 95, 73
and 57% would be used with the three surface areas used. The
Fig. 3 – 2-Microglobulin reduction percentage variations
based on the dialyser surface area, n=37, ANOVA
for repeated data.
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Fig. 4 – Myoglobin reduction percentage variations based
on the dialyser surface area, n=37, ANOVA for repeated
data.
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An issuewhichhasnot yet been resolved relates towhether
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ig. 5 – 1-Microglobulin reduction percentage variations
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reason, the prescribing physician has to assess that an ade-
quate minimum dose is reached. The convective effect is seen
with an improvement in 2-m clearance ranging from 1% to
5%. In the case of molecules with a greater molecular weight,
differences were only observed when using larger surface
areas compared to surface areas of 1.0m2.
If the limiting factor is the ultraﬁltration coefﬁcient, when
this UFC is greater than 45mL/h/mmHg, the differences
obtained in the convective volume and clearance capacity
would be minimal. Therefore, it seems reasonable to question
the beneﬁt of dialysers having a larger or smaller surface area
with UFCs greater than 45mL/h/mmHg, since they may obtain
an ultraﬁltration ﬂow greater than 8.1 L/h or 135mL/min,
above that which is usually used.
In the 90 s, in order to reduce dialysis duration, the Qb,
Qd and the dialyser surface areas were increased using in a
routine way surface areas ranging from 1.8 to 2.4m2. Subse-
quently, the national21 and international22 clinical guidelines
recommend a minimum of 12h weekly in order to recover the
importance of the dialysis time. However, despite recovering
the time factor, the tendency to use dialysers with larger sur-
face area has remained. As side effects, dialysers with larger
surface areamay showahigher incidence of headaches,23 par-
ticularly in women, greater albumin loss due to absorption,24
a platelet alteration determined as thrombopenia25 and may
cause a higher inﬂammatory stimulus derived from patients’
blood contact with a larger membrane surface. In several
works, it has been observed that immune system cells, even
from healthy subjects, upon contact with dialysis membranes
are immunologically activated,26,27 and this activation con-
tributes to perpetuating the microinﬂammation condition of
patients on haemodialysis. Therefore, when selecting a dial-
yser for a patient, it seems reasonable to choose that with
which a smaller surface area makes it possible to achieve
the same convection and clearance purpose. This surface area
reduction is accompanied by a price reduction since efﬁciency
is enhanced.
Conclusion
With the currently available high-ﬂow dialysers for OL-HDF
modalities, it is necessary to assess the selection of the dial-
yser surface area considering the cost-effectiveness ratio.
A smaller surface area may reduce side effects and decrease
the immunological and inﬂammatory response that is always
present in haemodialysis. In this work, the full use of the con-
vective capacity ranging from 57% to 95% has been observed
among the dialysers used, showing minimal differences both
in convective volume and clearance capacity when the UFC
is greater than 45mL/h/mmHg. It is advisable to optimise
dialyser output to the minimum surface area possible, adapt-
ing the treatment prescription, particularly of the Qb and the
duration.Conﬂicts of interest
The authors have no conﬂicts of interest to declare.
015
r
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2286 nefrolog ia. 2
Acknowledgements
This study was conducted with the support of the REDIN-REN
RD012 / 0021 network.
e f e r enc e s
1. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras
J, et al. High-efﬁciency postdilution online hemodiaﬁltration
reduces all-cause mortality in hemodialysis patients. J Am
Soc Nephrol. 2013;24:487–97.
2. Mostovaya IM, Blankestijn PJ, Bots ML, Covic A, Davenport A,
Grooteman MPC. Clinical evidence on hemodiaﬁltration:
a systematic review and a meta-analysis. Semin Dial.
2014;27:119–27.
3. Nistor I, Palmer SC, Craig JC, Saglimbene V, Vecchio M, Covic
A. Convective versus diffusive dialysis therapies for chronic
kidney failure: an updated systematic review of randomized
controlled trials. Am J Kidney Dis. 2014;63:954–67.
4. Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, et al. Mortality
and cardiovascular events in online haemodiaﬁltration
(OL-HDF) compared with high-ﬂux dialysis: results from the
Turkish OL-HDF Study. Nephrol Dial Transplant.
2013;28:192–202.
5. Grooteman MPC, van den Dorpel MA, Bots ML, Penne EL,
van der Weerd NC, Mazairac AH, et al. Effect of online
hemodiaﬁltration on all-cause mortality and cardiovascular
outcomes. J Am Soc Nephrol. 2012;23:1087–96.
6. Canaud B, Bowry SK. Emerging clinical evidence on online
hemodiaﬁltration: does volume of ultraﬁltration matter?
Blood Purif. 2013;35:55–62.
7. Maduell F, Ojeda R, Rodas L, Rico N, Fontseré N, Arias M.
Hemodiaﬁltración on-line con autosustitución: Valoración
de los cambios de ﬂujo de sangre sobre el volumen convectivo
y eﬁcacia. Nefrologia. 2015;35:50–7.
8. Maduell F, Arias-Guillen M, Fontseré N, Ojeda R, Rico N, Vera
M, et al. Elimination of large uremic toxins by a dialyzer
speciﬁcally designed for high-volume convective therapies.
Blood Purif. 2014;37:125–30.
9. De Sequera P, Albalate M, Pérez-García R, Corchete E, Puerta
M, Ortega-Díaz M, et al. Comparación de la eﬁcacia de dos
modalidades de hemodiaﬁltración en línea: mixta frente a
posdilucional. Nefrologia. 2013;33:779–87.
0. Ariza F, Merino A, Carracedo J, Alvarez de Lara MA, Crespo R,
Ramirez R, et al. Post-dilution high convective transport
improves microinﬂammation and endothelial dysfunction
independently of the technique. Blood Purif. 2013;35:
270–8.
1. Maduell F, Rodriguez N, Sahdala L, Coronel D, Arias M, Ojeda
R, et al. Repercusión de la actualización del software del
monitor 5008 en el volumen convectivo total. Nefrologia.
2014;34:599–604.
2. Molina Nún˜ez M, Roca Meron˜o S, de Alarcón Jiménez RM,
García Hernández MA, Jimeno Grin˜o C, Alvarez Fernández
2;35(3):280–286
GM, et al. Kt calculation as a quality indicator of
haemodialysis adequacy. Nefrologia. 2010;30:331–6.
3. Chapdelaine I, Mostovaya IM, Blankestijn P, Bots ML, van den
Dorpel MA, Lévesque R, et al. Treatment policy rather than
patient characteristics determines convection volume
in online post-dilution hemodiaﬁltration. Blood Purif.
2014;37:229–37.
4. Marcelli D, Scholz C, Ponce P, Sousa T, Kopperschmidt P,
Grassmann A, et al. High-volume postdilution
hemodiaﬁltration is a feasible option in routine clinical
practice. Artif Organs. 2014;39:142–9.
5. Cornelis T, van der Sande FM, Eloot S, Cardinaels E, Bekers O,
Damoiseaux J, et al. Acute hemodynamic response and
uremic toxin removal in conventional and extended
hemodialysis and hemodiaﬁltration: a randomized crossover
study. Am J Kidney Dis. 2014;64:247–56.
6. Bergström J, Wehle B. No change in corrected
2-microglobulin concentration after cuprophane
hemodialysis. Lancet. 1987;1:628–9.
7. Locatelli F, Altieri P, Andrulli S, Bolasco P, Sau G, Pedrini LA,
et al. Hemoﬁltration and hemodiaﬁltration reduce
intradialytic hypotension in ESRD. J Am Soc Nephrol.
2010;21:1798–807.
8. Tattersall JE, Ward RA, EUDIAL Group. Online
haemodiaﬁltration: deﬁnition, dose quantiﬁcation and safety
revisited. Nephrol Dial Transplant. 2013;28:542–50.
9. Wang AY, Ninomiya T, Al-Kahwa A, Perkovic V, Gallagher MP,
Hawley C, et al. Effect of hemodiaﬁltration or hemoﬁltration
compared with hemodialysis on mortality and cardiovascular
disease in chronic kidney failure: a systematic review
and meta-analysis of randomized trials. Am J Kidney Dis.
2014;63:968–78.
0. Sakurai K. Biomarkers for evaluation of clinical outcomes
of hemodiaﬁltration. Blood Purif. 2013;35 Suppl. 1:64–8.
1. Alcázar R, Maduell F, Martí A. SEN. Sociedad Espan˜ola de
Nefrología. Recognizing the different hemodialysis
modalities. Hemodialysis centers guides. Nefrologia. 2006;26
Suppl. 8:22–33.
2. Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B,
Fouque D, et al. EBPG guideline on dialysis strategies. Nephrol
Dial Transplant. 2007;22 Suppl. 2:ii5–21.
3. Sav MY, Sav T, Senocak E, Sav NM. Hemodialysis-related
headache. Hemodial Int. 2014;18:725–9.
4. Tomisawa N, Yamashita AC. Amount of adsorbed albumin
loss by dialysis membranes with protein adsorption. J Artif
Organs. 2009;12:194–9.
5. Prada L, Lee J, Gillespie A, Benjamin J. Thrombocytopenia
associated with one type of polysulfone hemodialysis
membrane: a report of 5 cases. Am J Kidney Dis.
2013;61:131–3.
6. Jimenez R, Carracedo J, Santamaría R, Soriano S, Maduen˜o JA,
Ramírez R, et al. Replicative senescence in patients with
chronic kidney failure. Kidney Int Suppl. 2005;99:S11–5.7. Aljadi Z, Mansouri L, Nopp A, Paulsson JM, Winqvist O,
Russom A, et al. Activation of basophils is a new and
sensitive marker of biocompatibility in hemodialysis. Artif
Organs. 2014;38:945–53.
